# Capillary Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/capillary-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.capillarybio.com
- Total disclosed funding: $2.9M
- Latest round: Seed (Aug 1, 2018)
- Investors on record: 1

## About

Capillary Biomedical, Inc. focuses on developing innovative biopharmaceutical products aimed at treating complex diseases, utilizing cutting-edge biotechnology to enhance patient outcomes and improve therapeutic efficacy.Founded in 2014, Capillary Biomedical, Inc. operates from its headquarters in Irvine, US. The company specializes in creating biopharmaceuticals that address critical health conditions, including cancer and autoimmune diseases. In July 2022, Capillary Biomedical was acquired by Tandem Diabetes Care Inc., although the financial terms of the acquisition were not disclosed. The company has secured funding through various rounds, including VENTURE DEBT, raising a total of USD 2.90 mn, with their latest investment of USD 1.50 mn coming from Leona M. and Harry B. Helmsley Charitable Trust. Paul Strasma serves as the CEO.Capillary Biomedical specializes in developing advanced biopharmaceutical products focused on treating various diseases through innovative therapeutic solutions. Their core offerings include proprietary formulations that utilize biotechnology to improve efficacy and patient outcomes, addressing critical health conditions like cancer and autoimmune diseases. Capillary Biomedical serves hospitals, clinics, and research institutions across North America, Europe, and Asia, ensuring a wide impact on patient care.Capillary Biomedical generates revenue through a strategic model involving direct sales and partnerships with healthcare providers. The company's transactional framework is primarily B2B, fostering long-term collaborations with hospitals and clinics. Transactions typically involve bulk purchases of their biopharmaceutical products, with structured pricing designed for accessibility while ensuring sustainable revenue streams for the company.Capillary Biomedical plans to utilize the proceeds from their most recent funding round to enhance their research and development efforts, aiming to launch new biopharmaceutical products designed to treat a broader range of diseases. The company is also focusing on expanding into new markets in Europe and Asia by 2024, aiming to establish a more significant presence in these regions. The acquisition by Tandem Diabetes Care Inc. may further facilitate these growth initiatives.

## Funding rounds

- Seed, Aug 1, 2018, $2.9M — Cove Fund

## Investors

- Cove Fund (https://capitalatlas.ai/funds/cove-fund) — Seed